Login
Mounjaro Can Now Be Given to Children as Young as 10, Rule European Drug Chiefs
Blockbuster weight-loss jab Mounjaro can now be prescribed to children as young as ten with type 2 diabetes, following new recommendations from Europe’s drugs watchdog. Until now, treatment options for children with type 2 diabetes — a condition that causes dangerously high blood sugar levels and raises the risk of heart disease, kidney failure and stroke — have largely been limited to metformin and insulin.
But the European Medicines Agency has now recommended extending the use of Mounjaro to younger patients, alongside a reduced-calorie diet and increased exercise, to help them better control their blood sugar and lose weight.
Tirzepatide, sold under the brand name Mounjaro in Europe, is already approved for both weight loss and uncontrolled type 2 diabetes in adults.
CCHR Documentary Investigates Psychiatric Drugs in Violence, Suicide Cases
Northeast Mississippi Daily Journal reported:
The two-hour documentary Prescription for Violence: Psychiatry’s Deadly Side Effects confronts a question long avoided: whether the rise in mass shootings, senseless violence, and suicides correlates with the dramatic increase in psychiatric drug use. The international mental health industry watchdog, Citizens Commission on Human Rights (CCHR), has released the documentary on its website, documenting how acts of mass violence have escalated to unprecedented levels alongside widespread psychiatric prescribing.
A National Institutes of Health–Centers for Disease Control investigation into this issue was announced earlier this year. CCHR says the documentary is especially timely. Drawing on case analyses from its global database of psychiatric drug-linked violence and suicide, the organization has documented over 100 high-profile acts of violence — including shootings and stabbings — committed by individuals taking or withdrawing from psychiatric drugs.
These incidents resulted in 532 deaths and 973 injuries. At least 39 involved school shootings or school-related violence.
The Meat Industry Is Sabotaging One of Modern Medicine’s Greatest Miracles
Around a decade ago, the U.S. implemented new rules to limit the widespread use of antibiotics in meat and dairy production, in an effort to combat the nation’s antibiotic resistance crisis. The regulations helped: Antibiotic sales for use on farms plunged by 43% from 2015 to 2017, and plateaued thereafter.
But now, that progress appears to be backsliding. According to recently published data from the Food and Drug Administration, sales of antibiotics for use in livestock surged by an alarming 15.8% in 2024 from the previous year. The sudden increase worries the scientists I spoke with who track the issue.
“It’s disappointing to see such a substantial increase,” Meghan Davis, a veterinarian and associate professor of environmental health and engineering at the Johns Hopkins Bloomberg School of Public Health, told me over email. “Antimicrobial use in food-producing animals matters for human health.”
America’s GLP-1 Weight-Loss Boom: A Quick Fix With Hidden Costs
GLP-1 (Glucagon-Like Peptide-1) agonist drugs (e.g., semaglutide, sold as Ozempic or Wegovy) are surging in popularity for obesity treatment. Roughly one in eight U.S. adults — about 12-13% — now take a GLP-1 medication, reflecting the immense appeal of these “skinny shot” injections amid a national obesity crisis. Yet as usage skyrockets, experts warn that relying on these drugs without changing diet or lifestyle could carry serious health risks.
Doctors emphasize that these medications don’t cure the underlying causes of obesity — they temporarily override them. “There’s a very understandable excitement…an agent that can achieve 15-20% weight loss truly opens a world of possibilities… However, food choices still matter. And the answer is a resounding yes,” says preventive cardiologist Dr. Stephen Devries via American Medical Association. In other words, even on high-octane weight-loss drugs, diet quality “remains a vital concern” for health.
As millions more people use GLP-1 agonists, a clearer picture of side effects and risks is emerging. These are not mild medicines; they profoundly alter gastrointestinal function and hormone levels. Common side effects hit many new users — about half report significant nausea and one-third experience diarrhea, especially in the initial weeks. These unpleasant effects are so widespread that they are often considered an expected part of treatment.
